Karyopharm Therapeutics Investor Presentation — February 2021

Document content

1 ©2021 KARYOPHARM THERAPEUTICS INC.

Investor Conference Call:

Fourth Quarter and Full Year

2020 Financial Results

February 11, 20212 ©2021 KARYOPHARM THERAPEUTICS INC.

2•Michael G. Kauffman , MD, PhD, Chief Executive Officer

•Mike Mason , MBA, Chief Financial OfficerPrepared

•John Demaree, Chief Commercial Officer

•Jatin Shah, MD, Executive Vice President, Chief Medical Officer

•Stephen Mitchener , Chief Business Officer

•Ian Karp , MBA, Senior Vice President, Investor and Public RelationsJoining for

Q&A SessionOn Today’s Call3 ©2021 KARYOPHARM THERAPEUTICS INC. This presentation contains forward- looking statements within themeaning ofThe Private Securities Litigation Reform Actof1995. Such forward- looking statements include those regarding

Karyopharm’s guidance onits2021 non-GAAP research anddevelopment andselling, general andadministrative expenses ;expectations andplans relating toXPOVIO forthetreatment ofpatients

with relapsed orrefractory multiple myeloma orrelapsed orrefractory diffuse large B-celllymphoma; commercialization ofXPOVIO oranyofitsdrug candidates andthecommercial performance of

XPOVIO ;submissions to,andthereview andpotential approval ofselinexor by,regulatory authorities, including theCompany's regulatory strategy, theanticipated availability ofdata tosupport such

submissions, timing ofsuch submissions andactions byregulatory authorities andthepotential availability ofaccelerated approval pathways ;theexpected design oftheCompany's clinical trials ;and

thetherapeutic potential ofandpotential clinical development plans forKaryopharm's drug candidates, especially selinexor .Such statements aresubject tonumerous important factors, risks and